These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22019134)

  • 1. A thickening network of lipids.
    Piomelli D
    Pain; 2012 Jan; 153(1):3-4. PubMed ID: 22019134
    [No Abstract]   [Full Text] [Related]  

  • 2. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
    Sasso O; Russo R; Vitiello S; Raso GM; D'Agostino G; Iacono A; La Rana G; Vallée M; Cuzzocrea S; Piazza PV; Meli R; Calignano A
    Pain; 2012 Jan; 153(1):33-41. PubMed ID: 21890273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia.
    Taylor BK
    Pain; 2013 Mar; 154(3):326-327. PubMed ID: 23333052
    [No Abstract]   [Full Text] [Related]  

  • 4. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide.
    Calignano A; La Rana G; Piomelli D
    Eur J Pharmacol; 2001 May; 419(2-3):191-8. PubMed ID: 11426841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
    Jaggar SI; Hasnie FS; Sellaturay S; Rice AS
    Pain; 1998 May; 76(1-2):189-99. PubMed ID: 9696473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
    Costa B; Comelli F; Bettoni I; Colleoni M; Giagnoni G
    Pain; 2008 Oct; 139(3):541-550. PubMed ID: 18602217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide.
    Bettoni I; Comelli F; Colombo A; Bonfanti P; Costa B
    CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):34-44. PubMed ID: 23394519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides as Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della Valle.
    Cuzzocrea S; Crupi R
    Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
    Esposito E; Cuzzocrea S
    Mini Rev Med Chem; 2013 Feb; 13(2):237-55. PubMed ID: 22697514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to dr. Kapoor.
    Sabato AF
    Pain Med; 2013 May; 14(5):775. PubMed ID: 23614877
    [No Abstract]   [Full Text] [Related]  

  • 11. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice.
    Luongo L; Guida F; Boccella S; Bellini G; Gatta L; Rossi F; de Novellis V; Maione S
    CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):45-54. PubMed ID: 23394524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging neuroprotective effects of N-palmitoylethanolamide besides its significant antinociceptive effects.
    Kapoor S
    Pain Med; 2013 May; 14(5):773-4. PubMed ID: 23581707
    [No Abstract]   [Full Text] [Related]  

  • 13. A role for the endogenous cannabinoid system in the peripheral control of pain initiation.
    Calignano A; La Rana G; Loubet-Lescoulié P; Piomelli D
    Prog Brain Res; 2000; 129():471-82. PubMed ID: 11098711
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of anorexia nervosa with palmitoylethanoamide.
    Scolnick B
    Med Hypotheses; 2018 Jul; 116():54-60. PubMed ID: 29857912
    [No Abstract]   [Full Text] [Related]  

  • 15. Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes.
    Donvito G; Bettoni I; Comelli F; Colombo A; Costa B
    CNS Neurol Disord Drug Targets; 2015; 14(4):452-62. PubMed ID: 25921749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.
    Gabrielsson L; Mattsson S; Fowler CJ
    Br J Clin Pharmacol; 2016 Oct; 82(4):932-42. PubMed ID: 27220803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    Haller VL; Cichewicz DL; Welch SP
    Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.
    Farquhar-Smith WP; Rice AS
    Anesthesiology; 2001 Mar; 94(3):507-13; discussion 6A. PubMed ID: 11374613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The palmitoylethanolamide family: a new class of anti-inflammatory agents?
    Lambert DM; Vandevoorde S; Jonsson KO; Fowler CJ
    Curr Med Chem; 2002 Mar; 9(6):663-74. PubMed ID: 11945130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
    Re G; Barbero R; Miolo A; Di Marzo V
    Vet J; 2007 Jan; 173(1):21-30. PubMed ID: 16324856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.